These results are a useful additional source of evidence about the relationship between CypA and MMP9 and Alzheimer’s disease risk, and they should be considered when appraising the likelihood that intervening on these targets will succeed in reducing Alzheimer’s disease risk. This evidence concerns the gene MMP9 and early-onset autosomal dominant Alzheimer disease.